Photo of Archit Bhatnagar

Partner in the General Corporate Practice at the Mumbai office of Cyril Amarchand Mangaldas. Archit specializes in mergers & acquisitions in the pharma, BFSI and FMCG space and has advised clients on a range of M&A transactions, including court-based mergers, business / asset transfers and share acquisitions. He can be reached at archit.bhatnagar@cyrilshroff.com

SEBI

Background

SEBI has been progressively tightening the regulatory regime surrounding transactions impacting listed entities – beginning with the implementation of the Kotak Committee recommendations on related party transactions (RPTs) through amendments to the LODR Regulations on May 9, 2018. Shortly thereafter, in November, 2019, SEBI constituted a Working Group (WG) to re-examine the RPT provisions of LODR Regulations, which resulted in the markets regulator notifying amendments on November 9, 2021, which took effect from April 01, 2022. These amendments brought about a paradigm shift by making the RPT approval and disclosure requirements applicable to listed companies in India very expansive and stringent.Continue Reading Proposed Amendments to LODR on Agreements Affecting Listed Companies – Swatting Flies with a Sledgehammer?

Covid-19 And M&A In India - Navigating Risks And Understanding Opportunities 

As the Covid-19 crisis deepens, and the number of positive cases and casualties continue to mount rapidly, governments across the world are enforcing stringent lockdown and social distancing measures. With the engines of economic growth grinding to a halt, the pandemic has mutated into an economic crisis, plunging the global economy into an unparalleled recession. India is no exception[1], and mergers and acquisitions (M&A) in India is sure to sniffle, snuffle and sneeze, at least in the short-term. From a legal standpoint, we believe that there will be consequent changes and fundamental shifts in the M&A landscape.
Continue Reading COVID-19 and M&A in India: Navigating Risks and Understanding Opportunities